gdc
LymphomaBiomarkersFDA Approvals, News & Updates

FDA Approved Xalkori for Young Patients with Anaplastic Large-Cell Lymphoma and ALK Mutation

In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation.
February 2021 Vol 7 No 1

In January 2021, the FDA approved Xalkori (crizotinib; from Pfizer), an oral ALK inhibitor, for the treatment of young patients aged 1 to 21 years who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) and ALK mutation.

Xalkori was previously approved for patients with metastatic non–small-lung cancer and ALK or ROS1 mutation.

This new indication for the targeted therapy Xalkori was based on the results of a single-arm clinical trial in 26 patients aged 1 to 21 years who had been diagnosed with relapsed or refractory ALCL and ALK mutation. The study did not include older people with this diagnosis. All the patients had previously received at least 1 systemic treatment for this diagnosis.

In the study, 20 patients received treatment with Xalkori at a dose of 280 mg/m2 twice daily and the other 6 patients received Xalkori at a dose of 165 mg/m2 twice daily, until their disease progressed or until they had unacceptable side effects. The patients were allowed to discontinue treatment with Xalkori therapy so they could have a stem-cell transplant if they wanted.

Of the 26 patients in the study, 23 (88%) patients had a response to Xalkori therapy; furthermore, 81% of these patients had a complete remission (no sign of disease). Among the 23 patients who had a response to therapy, 39% had a response lasting 6 months or more, and 22% had a response lasting 12 months or more.

The most common side effects were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, fever, abdominal pain, cough, and pruritus.

Serious side effects, including neutropenia and infection, occurred in 35% of the patients.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma. Ukoniq is used for MZL after 1 or more anti-CD20 therapies, and for follicular lymphoma after 3 or more lines of systemic therapy. Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy. Abecma is the first gene therapy approved by the FDA for the treatment of multiple myeloma.
Last modified: March 3, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country